Skip to main content

Andrew Berchuck, MD

Andrew Berchuck, MD
James M. Ingram Professor of Gynecologic Oncology
Campus Mail: 25171 Morris Bldg, Durham, NC 27710
Phone: (919) 684-3765
Email: berch001@mc.duke.edu

Dr. Andrew Berchuck is Director of the Duke Division of Gynecologic Oncology and holds the James M. Ingram Distinguished Professorship. He is a practicing oncologist who is actively involved in the surgical and chemotherapy management of women with ovarian, endometrial and lower genital tract cancers. This includes minimally invasive laparoscopic surgical approaches. He also has developed a research program that focuses on the molecular-genetic alterations involved in malignant transformation of the ovarian and endometrial epithelium. He has published over 300 peer-reviewed papers in these areas. The objectives of his research include 1) identification of ovarian cancer susceptibility polymorphisms through a population-based case-control molecular epidemiologic study, and 2) use of genomic approaches  to elucidate the molecular heterogenetity of ovarian cancer. Thirty fellows and residents have worked in his lab, several of whom are now funded investigators. His research efforts have been recognized nationally and he has received awards for best oral presentation at the annual meetings of both the Society of Gynecologic Oncology and the International Gynecologic Cancer Society. Dr. Berchuck was awarded the Barbara Thomason Ovarian Cancer Research Professorship by the American Cancer Society in 2006. He has served as editor of several books in the field including Principles and Practice of Gynecologic Oncology. Dr. Berchuck also has a major commitment to national activities, and was President of the Society of Gynecologic Oncology in 2008. He served as chair of the scientific advisory committee of the Ovarian Cancer Research Fund (http://www.ocrf.org) in New York City. Finally, he is also head of the steering committee of the international Ovarian Cancer Association Consortium (OCAC), a group of 50 case-control studies that are working together to identify ovarian cancer susceptibility polymorphisms (www.srl.cam.ac.uk/consortia/ocac/index.html).

Education and Training

  • M.D., Case Western Reserve University, 1980

Research

Dr Berchuck is interested in the molecular pathogenesis of ovarian and endometrial cancer. 

View Publications

Selected Grants and Awards

Publications

Rodriguez, GC, Clarke-Pearson, DL, Soper, JT, Berchuck, A, Synan, I, and Dodge, RK. "The negative prognostic implications of thrombocytosis in women with stage IB cervical cancer." Obstetrics and Gynecology 83, no. 3 (March 1994): 445-448.

Scholars@Duke

Kerns, BJ, Jordan, PA, Faerman, LL, Berchuck, A, Bast, RC, and Layfield, LJ. "Determination of proliferation index with MIB-1 in advanced ovarian cancer using quantitative image analysis." Am J Clin Pathol 101, no. 2 (February 1994): 192-197.

Scholars@Duke

Berchuck, A, Kohler, MF, Hopkins, MP, Humphrey, PA, Robboy, SJ, Rodriguez, GC, Soper, JT, Clarke-Pearson, DL, and Bast, RC. "Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors." Gynecol Oncol 52, no. 2 (February 1994): 232-236.

Full Text

Bast, RC, Xu, F, Yu, Y, Crews, J, Argon, Y, Maier, L, Lidor, Y, Berchuck, A, and Boyer, CM. "Additive and synergistic interactions of monoclonal antibodies and immunotoxins reactive with breast and ovarian cancer." Immunol Ser 61 (1994): 23-30. (Review)

Scholars@Duke

Soper, JT, Evans, AC, Clarke-Pearson, DL, Berchuck, A, Rodriguez, G, and Hammond, CB. "Alternating weekly chemotherapy with etoposide-methotrexate-dactinomycin/cyclophosphamide-vincristine for high-risk gestational trophoblastic disease." Obstet Gynecol 83, no. 1 (January 1994): 113-117.

Scholars@Duke

Brûle, FAVD, Berchuck, A, Bast, RC, Liu, F-T, Gillet, C, Sobel, ME, and Castronovo, V. "Differential expression of the 67-kD laminin receptor and 31-kD human laminin-binding protein in human ovarian carcinomas." European Journal of Cancer 30, no. 8 (1994): 1096-1099.

Scholars@Duke

van den Brûle, FA, Berchuck, A, Bast, RC, Liu, FT, Gillet, C, Sobel, ME, and Castronovo, V. "Differential expression of the 67-kD laminin receptor and 31-kD human laminin-binding protein in human ovarian carcinomas." Eur J Cancer 30A, no. 8 (1994): 1096-1099.

Scholars@Duke

Liu, FS, Kohler, MF, Marks, JR, Bast, RC, Boyd, J, and Berchuck, A. "Mutation and overexpression of the p53 tumor suppressor gene frequently occurs in uterine and ovarian sarcomas." Obstet Gynecol 83, no. 1 (January 1994): 118-124.

Scholars@Duke

Berchuck, A, Kohler, MF, Marks, JR, Wiseman, R, Boyd, J, and Bast, RC. "The p53 tumor suppressor gene frequently is altered in gynecologic cancers." American Journal of Obstetrics and Gynecology 170, no. 1 (January 1, 1994): 246-252.

Full Text

Berchuck, A, Kohler, MF, Marks, JR, Wiseman, R, Boyd, J, and Bast, RC. "The p53 tumor suppressor gene frequently is altered in gynecologic cancers." Am J Obstet Gynecol 170, no. 1 Pt 1 (January 1994): 246-252. (Review)

Scholars@Duke

Pages